AbbVie Shares Purchased by JB Capital LLC

Institutional investor boosts stake in pharmaceutical giant

Apr. 5, 2026 at 10:07am

Got story updates? Submit your updates here. ›

JB Capital LLC increased its position in AbbVie Inc. (NYSE:ABBV) by 269.7% in the fourth quarter, according to a recent SEC filing. The firm now owns 16,913 shares of the company's stock, valued at $3.86 million.

Why it matters

AbbVie is a major pharmaceutical company with a diverse product portfolio, including immunology, oncology, and women's health drugs. Institutional investors closely track ownership changes in large-cap healthcare stocks like AbbVie, as they can signal broader market sentiment and investment trends.

The details

According to the SEC filing, JB Capital LLC acquired an additional 12,338 shares of AbbVie during the fourth quarter, bringing its total position to 16,913 shares. This represents a significant 269.7% increase in the firm's AbbVie holdings compared to the prior quarter.

  • The filing covers the fourth quarter of 2025.
  • JB Capital LLC's increased stake was reported on April 5, 2026.

The players

JB Capital LLC

An institutional investment firm that manages a portfolio of stocks, bonds, and other assets.

AbbVie Inc.

A global biopharmaceutical company that develops and markets therapies for complex and chronic medical conditions.

Got photos? Submit your photos here. ›

The takeaway

The increased stake by JB Capital LLC in AbbVie suggests the firm sees long-term value in the pharmaceutical company's diversified drug portfolio and growth prospects. This type of institutional investment activity is closely watched by analysts and investors as an indicator of market sentiment.